Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations.
Curr Res Transl Med
January 2025
Department of Diabetology and Endocrinology, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India.
Drug repurposing is a promising strategy for managing cardiovascular disease (CVD) in geriatric populations, offering efficient and cost-effective solutions. CVDs are prevalent across all age groups, with a significant increase in prevalence among geriatric populations. The middle-age period (40-65 years) is critical due to factors like obesity, sedentary lifestyle, and psychosocial stress.
View Article and Find Full Text PDFThe effect of azithromycin treatment on respiratory morbidity in children with down syndrome.
BMC Pediatr
January 2025
Pediatric Pulmonary Unit, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University, Yitzhak Rager Ave, PO Box 151, Beer Sheva, 8410101, Israel.
Background: Children with Down syndrome (DS) often experience recurrent and prolonged hospitalizations from respiratory infections. While Azithromycin has been increasingly used for lower-respiratory tract infections (LRTIs) in children, its potential benefits for DS patients are unexplored. This study evaluates the effect of chronic azithromycin treatment on respiratory morbidity in children with DS.
View Article and Find Full Text PDF[Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive pneumonia in children].
Zhongguo Dang Dai Er Ke Za Zhi
December 2024
Department of Pediatrics, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Objectives: To investigate the efficacy and safety of prolonged azithromycin (PAZM) versus switching to doxycycline (SDXC) in the treatment of macrolide-unresponsive pneumonia (MUMPP) in children.
Methods: A total of 173 children with MUMPP who were hospitalized in Baoji Central Hospital, from January to December 2023 were selected as subjects. According to the choice of secondary antibiotic after 72 hours of initial macrolide therapy, they were divided into two groups: PAZM and SDXC.
Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients.
BMC Cardiovasc Disord
December 2024
Community Memorial Hospital, Ventura, CA, USA.
Objective: Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac), was used as a multidrug therapy method to treat COVID-19 illness and superimposed secondary bacterial pneumonia. Concerns have been raised though about such combinations regarding cardiac QTc interval prolongation and risks of arrhythmias, which we set out to address in this study.
Design: We evaluated cardiac safety in a Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infections study, conducted by ProgenaBiome.
Molecular characteristics, clonal transmission, and risk factors of among hospitalized patients in a tertiary hospital in Ningbo, China.
Front Microbiol
December 2024
School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, China.
Background: Nosocomial transmission of infection (CDI) has been documented in Ningbo, China. However, data on molecular characteristics, clonal transmission, and risk factors of CDI in this region remain limited.
Methods: A cross-sectional study enrolled hospitalized patients with diarrhea during September to November 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!